Adams, S <br/><br/>
Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase II KEYNOTE-086 study.  [electronic resource] 

 -  Annals of oncology : official journal of the European Society for Medical Oncology  03 2019 
 - 405-411 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1569-8041 
<br/><br/><label>Standard No.: </label>10.1093/annonc/mdy518  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Antibodies, Monoclonal, Humanized--administration & dosage<br/>B7-H1 Antigen--genetics<br/>Cohort Studies<br/>Female<br/>Gene Expression Regulation, Neoplastic--drug effects<br/>Humans<br/>Middle Aged<br/>Neoplasm Metastasis<br/>Progression-Free Survival<br/>Triple Negative Breast Neoplasms--drug therapy